Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AMAb90964 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#AMAb90964, RRID:AB_2665736
- Product name
- Anti-TUFM
- Antibody type
- Monoclonal
- Description
- Monoclonal Antibody against Human TUFM, Clone ID: CL2242, Gene description: Tu translation elongation factor, mitochondrial, Alternative Gene Names: EF-TuMT, EFTu, Validated applications: WB, IHC, ICC, Uniprot ID: P49411, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- CL2242
- Vial size
- 100 µl
- Concentration
- 1.0 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Prenylcysteine oxidase 1, an emerging player in atherosclerosis
BioID reveals an ATG9A interaction with ATG13‐ATG101 in the degradation of p62/SQSTM1‐ubiquitin clusters
Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration
Banfi C, Baetta R, Barbieri S, Brioschi M, Guarino A, Ghilardi S, Sandrini L, Eligini S, Polvani G, Bergman O, Eriksson P, Tremoli E
Communications Biology 2021;4(1)
Communications Biology 2021;4(1)
BioID reveals an ATG9A interaction with ATG13‐ATG101 in the degradation of p62/SQSTM1‐ubiquitin clusters
Kannangara A, Poole D, McEwan C, Youngs J, Weerasekara V, Thornock A, Lazaro M, Balasooriya E, Oh L, Soderblom E, Lee J, Simmons D, Andersen J
EMBO reports 2021;22(10)
EMBO reports 2021;22(10)
Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration
Zottel A, Jovčevska I, Šamec N, Mlakar J, Šribar J, Križaj I, Skoblar Vidmar M, Komel R
Therapeutic Advances in Medical Oncology 2020;12
Therapeutic Advances in Medical Oncology 2020;12
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-TUFM antibody. Remaining relative intensity is presented. Loading control: Anti-PPIB.
- Sample type
- Human
- Protocol
- Protocol
